Fulcrum Therapeutics Inc

NASDAQ:FULC  
12.56
-0.21 (-1.64%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)397.74M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.63 Million
Adjusted EPS-$0.72
See more estimates
10-Day MA$13.31
50-Day MA$12.55
200-Day MA$13.04
See more pivots

Fulcrum Therapeutics, Inc. Stock, NASDAQ:FULC

26 Landsdowne Street, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.651.8851
Number of Employees: 73

Description

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.